Dan Kidle joined Arboretum Ventures in 2011 as an Analyst.
In his current role as Principal, Dan focuses on supporting Arboretum's portfolio companies and leading new investments across the firm’s sectors of interest, with particular emphasis on life science tools. Since joining Arboretum, Dan has undertaken significant due diligence responsibilities to support more than a dozen of Arboretum’s new and follow-on investments, including Ebb Therapeutics, NeuMoDx, IntelliCyt, Rethink, Cardiac Dimensions, Strata Oncology, SI-BONE, Swift Biosciences and Dropworks. Dan’s portfolio company involvement has included serving on the board of directors for life science tools company IntelliCyt. Dan currently serves on the Board of Directors for Swift Biosciences, Dropworks and as a board observer for NeuMoDx and Strata Oncology.
Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations.